Accessibility

Health

Connecting New Business Grads With Genomics Innovators

Genomic tools and technologies have the potential to improve our health, environment and nutrition, and Alberta has no shortage of entrepreneurs ready to meet the challenge. However, while biotech startups are typically well-equipped to test and refine their technologies and products, scaling-up into a sustainable business presents a wholly new challenge. A 2025 survey conducted […]

Connecting New Business Grads With Genomics Innovators Read More »

From Discovery to Market II: Nova Medical Testing Inc.

From Lab Discovery to Global Impact: How Nova Medical Testing Inc. is Advancing Metabolomics in Alberta and Beyond   In the world of life sciences, timing is everything. While genomics can help predict what might happen in the body, metabolomics reveals what has already happened and provides a powerful perspective that is becoming increasingly important

From Discovery to Market II: Nova Medical Testing Inc. Read More »

From Discovery to Market: Alberta Life Sciences Companies Creating Real Value

Alberta is in the midst of a transformation. Alongside the oil sands and the agricultural industries that have long defined its economy, a new sector is taking shape: a growing life sciences industry that is converting university research into patented technologies, commercialized products, and competitive companies with global reach. The numbers tell a compelling story,

From Discovery to Market: Alberta Life Sciences Companies Creating Real Value Read More »

David Bailey, President and CEO, Genome Alberta; Rob Annan, President and CEO, Genome Canada; Karim Bardeesy, Parliamentary Secretary to the Minister of Industry, holding a sign that says "Canadian Genomics Strategy" and smiling at the camera.

Canada Invests in Genomics R&D to Accelerate Industry Growth and Technology Adoption

Federal investment through Genome Canada and the regional Genome Centres helps Canadian companies use genomics and biotech innovation to grow while unlocking private sector co-investment in research and development (R&D). March 18, 2026 — Today, on behalf of the Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions,

Canada Invests in Genomics R&D to Accelerate Industry Growth and Technology Adoption Read More »

Image on the left: Dr. David Wishart giving a speech at the podium. Image on the right: Dr. Wishart posing with the award with Gijs Gijs van Rooijen, Chief Scientific Officer, Genome Alberta

ASTech Award Honours Dr. David Wishart for World-Leading Contributions in AI/ML Innovation

As data becomes the engine driving modern discovery, Dr. David Wishart stands at the forefront in building the datasets and AI tools that use information to power innovation. A globally recognized leader in metabolomics and precision health, Dr. Wishart was honoured with the ASTech Award in the AI/ML Advancement and Application category, for his groundbreaking

ASTech Award Honours Dr. David Wishart for World-Leading Contributions in AI/ML Innovation Read More »

A group of friends smiling while hanging out outdoors

From Trial and Error to Optimized Care: How Genomics is Personalizing Mental Health Treatment

Many Albertans are impacted by mental health disorders or know a loved one who is. Mental health disorders are complex, with numerous genetic, social and environmental factors, and it can be hard to predict how a patient will respond to different medications or strategies. For some Albertans, finding a more direct path to an effective

From Trial and Error to Optimized Care: How Genomics is Personalizing Mental Health Treatment Read More »

Design with text saying "New Investment in Biotech - Prostate Cancer Diagnostic"

Biotech Investment set to Transform Prostate Cancer Diagnosis across Canada

Alberta-based precision health company aims to deliver more precise testing for a leading cause of death among men while minimizing the risks of overdiagnosis.   Calgary – June 26, 2025 – Today, new investments into public-private R&D projects were announced as part of a new wave of new Genome Canada R&D investments supporting the Canadian

Biotech Investment set to Transform Prostate Cancer Diagnosis across Canada Read More »

Accelerating Health Outcomes for Patients Through Precision Medicine and Advancing Genetic Testing in Routine Care

New investments are helping bring technology to patients, making it faster to test, diagnose, or treat health conditions, and improve the delivery of personalized medicine in Alberta and BC.   April 15, 2025 Calgary, Alberta – Genome Alberta and Genome British Columbia (Genome BC), with support from Government of Alberta and other key partners, are

Accelerating Health Outcomes for Patients Through Precision Medicine and Advancing Genetic Testing in Routine Care Read More »

CPHI graphic showing the initiative's logo and two images of patients interacting with doctors.

New Investments to Drive Precision Health and Economic Growth through Genomics Data Initiative

Alberta to drive Canada’s competitive edge in health innovation using AI-powered genome sequencing data for more precise, preventative and cost-effective health care.   Calgary, Alberta – March 5, 2024 – Today, new investments into Alberta initiatives were announced as part of the Canadian Precision Health Initiative (CPHI) led by Genome Canada. This $81 million in

New Investments to Drive Precision Health and Economic Growth through Genomics Data Initiative Read More »

Scroll to Top
Share
Copy Link